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Abstract
The shape of the human face and skull is largely genetically determined, but the genetic drivers of
craniofacial morphology remain poorly understood. Here we used a combination of epigenomic
profiling, in vivo characterization of candidate enhancer sequences in transgenic mice, and
targeted deletion experiments to examine the role of distant-acting enhancers in craniofacial
development. We identified complex regulatory landscapes, consisting of enhancers that drive a
remarkable spatial complexity of developmental expression patterns. Deletion of individual
craniofacial enhancers from the mouse genome resulted in significant alterations of craniofacial
shape, demonstrating their functional importance in defining face and skull morphology. These
results demonstrate that enhancers play a pervasive role in mammalian craniofacial development
and suggest that enhancer sequence variation contributes to human facial morphology.
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Introduction
The shape of the face is one of the most distinctive features among humans, and differences
in facial morphology have substantial implications in many areas, including social
interaction, psychology, forensics, and clinical genetics (1–3). The resemblance of facial
shapes within families in general, and between monozygotic twins in particular, suggests a
major contribution of genetic factors to craniofacial morphology (4–6). Many protein-coding
genes whose disruption causes major aberrations of craniofacial morphology are known.
This includes pathological dysmorphologies of the face itself, such as clefts of the lip or
palate, as well as distinctive facial features associated with genetic syndromes that are
indicative of associated pathologies in other organ systems (7–14). In contrast to these
disease-associated genes, the genetic drivers of normal craniofacial variation remain poorly
understood. A small number of candidate genes have been implicated in variation of
craniofacial shape through genome-wide association studies, but collectively they explain
only a minute fraction of the morphological variation observed in human populations (15–
17). It remains a central question how complex traits such as the overall shape of the face
can be modulated in quantitatively subtle ways, while avoiding the often severe
consequences associated with protein-coding mutations (18).
Recent observations of large numbers of distant-acting transcriptional enhancers in
mammalian genomes (19, 20) raise the possibility that these sequences play a significant
role in the development of structures like the craniofacial complex. Enhancers typically have
highly restricted in vivo activity patterns and often control the expression of their target
genes in a modular fashion, where different enhancers activate the expression of the same
gene in different cell types, anatomical regions, or at different developmental time points
(21). In principle, such complex arrays of enhancers acting on individual genes may provide
a general mechanism for the independent fine tuning of distinct aspects of gene expression
in different developmental processes, which in turn may affect specific phenotypic traits
including facial shape (22). This model is consistent with the extensive studies of the genes
and gene regulatory networks involved in the development of the neural crest, a cell
population contributing to multiple tissues including facial bone and cartilage (23). In-depth
studies of individual genes involved in neural crest development (e.g., (24–26)), as well as
genome-wide studies of regulatory sequences active in human neural crest cells (27) support
that many genes involved in craniofacial development are associated with complex
regulatory architecture. However, owing to the lack of systematic genome-scale in vivo
studies, the genomic location and spatiotemporal activity patterns of such craniofacial in
vivo enhancers remain poorly understood. In the present study we use an epigenomic
method on whole face tissue to explore the genome-wide landscape of craniofacial
enhancers, and study their involvement in defining craniofacial morphology using large-
scale transgenic reporter assays and enhancer knockout studies in mice.
Identification of in vivo Craniofacial Enhancers
To identify craniofacial developmental enhancers on a genome-wide scale, we performed
ChIP-seq analysis on mouse embryonic day (e) 11.5 facial tissue with the enhancer-
associated p300 protein (21) (fig. 1). At this developmental time point, key events of
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craniofacial development are in progress, including growth and morphogenetic processes
affecting the size, shape and structure of all major craniofacial prominences (28, 29). All
major facial subregions were included in this tissue preparation (30), building on the
previously described efficiency of this inclusive approach to identify enhancers with both
broad and tightly confined patterns in subregions of developing embryonic structures (31,
32).
Enrichment analysis identified 4,399 distal candidate enhancers genome-wide, defined as
regions that showed significant p300 binding in craniofacial tissue and were at least 2.5kb
from known transcription start sites (fig. 2, table S1 and S2). Candidate enhancers were
located at a median distance of 44kb from the nearest transcript start site, with 38.4% in
introns of genes and 54.7% located in non-coding regions outside of genes (intergenic). The
majority of candidate enhancers also showed evidence of significant evolutionary constraint
(87.5%, table S1) and had unique orthologous sequences in the human genome (96.7%).
Unbiased ontology analysis (33) revealed that candidate craniofacial enhancers are enriched
near genes that are known to cause craniofacial phenotypes when deleted in mouse models
or mutated in humans (table 1). Candidate craniofacial enhancers were also significantly
enriched at loci implicated in human craniofacial traits and birth defects through genome-
wide association studies (fig. S1). These observations are consistent with a role of the
identified enhancer candidate sequences in the regulation of genes with known roles in
craniofacial development. Taken together, these results suggest that thousands of distant-
acting enhancers are involved in orchestrating the genome-wide gene expression landscape
during craniofacial development.
Large-scale Transgenic Analysis of Craniofacial Enhancers
ChIP-seq performed directly on craniofacial tissues provided a genome-wide catalogue of
sequences that are likely to be active in vivo enhancers during craniofacial development at
e11.5. However, this approach does not provide direct insight into the exact activity patterns
of individual candidate enhancer sequences. To examine craniofacial enhancer activity
patterns in detail, we used transgenic enhancer reporter assays in mice, coupled to high-
resolution three-dimensional mapping of LacZ reporter activities by optical projection
tomography (OPT) (fig. 1 and (30)) (41, 42). Since many, but not all in vivo enhancers can
be identified by p300 binding (43), we also considered sequence conservation (41) and
proximity to genes or loci with a known role in craniofacial development as additional
criteria in the selection of candidate sequences. In total, we tested 205 candidate sequences
in transgenic mice, with the majority (123 or 60%) located within or near regions associated
with craniofacial development through experimental, genetic or genome-wide association
studies (see table S3 for properties of all tested candidate sequences). Each candidate
enhancer sequence was coupled to a minimal promoter and used to generate multiple
transgenic embryos by pronuclear injection (30). Only patterns that were independently
observed in at least three different embryos were considered reproducible. In total, 121 of
205 tested sequences showed reproducible reporter gene expression in at least one
craniofacial structure. We further extended the set of in vivo characterized craniofacial
enhancers by re-examining data from previously described large-scale enhancer screens not
specifically targeted at craniofacial enhancer discovery (21, 31, 32, 41, 44–46), providing an
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additional 75 craniofacial enhancers (table S3). Transgenic results for all 196 craniofacial
enhancers identified or re-examined in this study are available through the Vista Enhancer
Browser (http://enhancer.lbl.gov) or the NIDCR FaceBase consortium web site (http://
facebase.org) (47).
To gain higher-resolution insight into the three-dimensional activity patterns of craniofacial
enhancers in the context of developing embryos, we used optical projection tomography
(OPT). In total, representative embryos for 55 craniofacial enhancers, including 48 that were
newly identified in this study, were analyzed by OPT. Selected examples of three-
dimensional views are provided as supplementary movies (movies S1–S11). More
comprehensive OPT data collections can be interactively explored through a dedicated
viewer at the NIDCR FaceBase database (see fig. S2) (47). Examination of this large set of
in vivo-validated and characterized craniofacial enhancers highlights several salient features
and resulting potential applications of these data sets, which we will describe using selected
examples. Specifically, this collection of enhancers 1) identifies a remarkable diversity of
enhancer activity patterns, highlighting the regulatory complexity of the genetic code; 2)
enables the dissection of the regulatory landscapes of individual genes known to be involved
in craniofacial development; 3) provides a starting point for the mechanistic exploration of
genomic intervals implicated in craniofacial development through genome-wide association
studies.
Diversity of Patterns
To illustrate the reproducibility and diversity of craniofacial activity patterns identified in
transgenic embryos, selected examples of enhancers identified in this study are shown in fig.
3A. For all craniofacial prominences (medial nasal, lateral nasal, maxillary, and
mandibular), structure-specific active enhancers were identified (see fig. 3A and S4A for a
schematic view of the e11.5 mouse face). In depth analysis of craniofacial activity patterns
through the combined use of whole-mount LacZ staining and OPT imaging revealed that in
many cases only subregions of these structures were reproducibly targeted by an enhancer.
For example, enhancer mm387 drives expression in the anterior part of the maxillary
prominence while enhancer mm458 is restricted to a posterior ventral region (fig. 3B, top).
Similar region-specific activities are observed in other facial substructures such as the nose,
where enhancer mm933 is active in the medial nasal prominence, while the activity of
enhancer mm426 is confined to the lateral nasal prominence (fig. 3B, top). OPT scans of
whole-mount embryos provide additional spatial information about enhancer activity pattern
by capturing the activity signal in internal embryonic structures (fig. 3B, bottom). These
data highlight the complexity, diversity, and spatially highly restricted activity patterns of
distant-acting enhancer sequences active during craniofacial development.
Regulatory Landscapes of Craniofacial Genes
Systematic screening of individual genomic loci via ChIP-seq followed by transgenic
characterization enables functional dissection of the distant-acting enhancer landscapes of
individual genes with known roles in craniofacial development. As an example, mouse Msx1
and human MSX1 have been extensively studied for their role in craniofacial development
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(supplementary online text and (48)). Msx1 is surrounded by several hundred kilobases of
non-coding DNA, which renders the search for distant-acting enhancers by tiling approaches
challenging. Transgenic testing of seven candidate sequences identified by ChIP-seq and
located up to 235kb away from the Msx1 transcription start site resulted in the identification
of five distinct craniofacial enhancers potentially regulating its expression (fig. 4A). At
e11.5, each of these enhancers drove patterns that partially recapitulated the endogenous
Msx1 RNA expression. For instance, Msx1 activity in the second branchial arch and in the
maxillary process of the e11.5 embryo is recapitulated by the combined activity of two
separate enhancers located at 1kb and 235kb upstream of the promoter (mm426 and hs746,
fig. 4A). These observations support the notion that complex spatial expression patterns of
key developmental genes are driven by modular arrays of distant-acting enhancers (49) and
highlights the potential of enhancers to provide a mechanism for fine tuning of in vivo gene
expression patterns.
Craniofacial Enhancers within Disease-Associated Intervals
To illustrate the utility of these enhancer datasets in the follow-up of genome-wide
association, population scale sequencing, and candidate locus studies, 50 candidate
enhancers mapping to intervals implicated in craniofacial morphology or orofacial birth
defects through human genetic studies were included in the transgenic assays (see table S3).
Trait-associated variants that map to non-coding genome regions or are not linked to any
protein-altering variants are a common challenge in the interpretation of such genetic
studies. A prototypical example is the gene desert at human chromosome 8q24. A 640kb
region in this interval is devoid of protein-coding genes, but is a major susceptibility locus
for cleft palate with a calculated population attributable risk of 41% (35, 52, 53) and is
significantly linked to normal variation in several facial morphology traits (16). We
identified four craniofacial enhancer candidate sequences in this risk interval, two of which
drive reproducible craniofacial reporter activity at e11.5 in transgenic mice (fig. 4B). As a
second example, we examined the 1p22 locus. In this interval, markers located near and
within the ABCA4 gene are associated with an increased risk for cleft palate, but it remains
unclear whether these variants are linked to deleterious protein-coding mutations of ABCA4
(36, 54). Based on RNA expression data the neighboring gene ARHGAP29, rather than
ABCA4 itself, has been proposed to be causatively involved in craniofacial development
(55). However, ARHGAP29 falls outside the genomic boundaries of the risk-associated
linkage block. By scanning the region comprising these two genes for possible associated
enhancers, we identified a human-mouse conserved sequence in the first intron of Abca4
that drove highly reproducible reporter activity in the facial midline, a pattern reminiscent of
Arhgap29 RNA expression, suggesting that this enhancer may drive expression of Arhgap29
during craniofacial development (fig. 4C and movie S10) (56). A causative effect of
sequence or copy number variants in these particular enhancers on craniofacial morphology
remains to be demonstrated, furthermore we cannot exclude the existence of additional
enhancer sequences at these loci that were not captured in the present screen. These possible
limitations notwithstanding, our results illustrate the utility of collections of validated
enhancers as starting points for the mechanistic interpretation of human genetic studies by
linking functional genomic and human genetic data sets.
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Targeted Deletions of Craniofacial Enhancers
The existence of large numbers of distant-acting enhancers with precise tissue-specific
activities during craniofacial development raises the question of their functional impact on
craniofacial morphology through the regulation of their respective target genes. To examine
such contributions in more detail, we selected three enhancers with highly reproducible
craniofacial activity patterns and explored their functions through targeted deletions in mice
(fig. 1). The three enhancers, termed hs1431 (near Snai2), hs746 (near Msx1) and hs586
(near Isl1), were chosen based on their association with known craniofacial genes (7, 57, 58)
(see supplementary online text), the robustness of their activity patterns, and the absence of
additional known enhancers with overlapping activity near the same gene. Furthermore, the
in vivo activity patterns driven by these enhancers partially recapitulate the known
expression patterns of their presumptive target genes (fig. 4A and fig. S3). The enhancers
were intentionally chosen from different, functionally unrelated loci in order to provide a
representative sample of the genome-wide enhancer data set, rather than an in-depth
exploration of a single gene or pathway. All selected enhancers are located at a very long
distance from their respective target genes (350kb, 235kb and 190kb respectively) and are
active in the craniofacial complex through multiple stages of embryonic development (fig.
4A, fig. S3, fig. 5 and movies S1–S9).
To test if these enhancers play a role in modulating craniofacial morphology, we created
three separate mouse lines carrying deletion alleles for each of the three enhancers using a
standard homologuous recombination strategy in embryonic stem cells (30). Mice
homozygous for any of the three enhancer deletions do not display gross craniofacial
malformations or other obvious deficiencies. To evaluate the effect of each enhancer
deletion on the expression of the presumptive target genes (Snai2, Msx1 and Isl1), we used
quantitative RT-PCR to measure transcript levels in different craniofacial structures of
individual wild-type and enhancer deletion embryos (littermates) at e11.5 and e13.5 (fig. 6
and fig. S4). Depending on time-point and substructure, we observed up to 3.9-fold down-
regulation (P=4e-05) of Snai2 in homozygous Δhs1431 embryos, 1.5-fold down-regulation
(P=0.015) of Msx1 in Δhs746 and 1.3-fold down-regulation (P=0.04) of Isl1 in Δhs586 (fig.
6C, D and fig. S4E). Notably, in all cases the changes in transcript levels of the respective
target gene were confined to subregions in which the enhancer was active. However, not all
subregions with enhancer reporter activity showed significant down-regulation of the target
gene. These observations raise the possibility of partial functional redundancy between the
enhancers studied here and overlapping regulatory activities from gene promoters or
additional distant-acting enhancers that were not captured in our genome-wide screen.
Regardless of the presence of possible additional regulatory sequences in these genome
intervals, these results provide direct evidence for the requirement of enhancers for normal
gene expression during craniofacial development.
To examine if the deletion of these enhancers had a significant impact on craniofacial
development beyond expression phenotypes, we compared mouse skulls from wild-type and
enhancer deletion mice at eight weeks of age. Since it is challenging to quantify possible
differences in craniofacial morphology by visual observation alone, we used micro-
computed tomography (micro-CT) to obtain accurate three-dimensional measurements of
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the skulls. Three cohorts, each consisting of at least 30 mice homozygous for a deletion of
one of the three enhancers, were compared to a cohort of 44 wild-type littermates. Micro-CT
reconstructions of each mouse head were measured using 54 standardized skeletal
landmarks (fig. S5). The cohorts of wild-type and enhancer deletion mice were compared
using canonical variate analysis (CVA) to identify possible changes in craniofacial
morphology resulting from the enhancer deletions (fig. 7). Procrustes ANOVA (F=12.0,
p<0.0001) and MANOVA (Pillau’s Trace 2.5, p<0.0001) tests both showed that enhancer
deletion genotypes were significantly associated with alterations of craniofacial shape. All
individual pair-wise permutation tests (Procrustes distances) between wild-type and
enhancer deletion lines revealed significant differences (table S4), with the most pronounced
differences observed for Δhs1431 and Δhs746 (both P<0.0001 compared to wild-type).
Differences between wild-type, Δhs1431, and Δhs746 mice were also significant after
Bonferroni adjustment for the 6 pairwise comparisons between groups. The largest
magnitude of effect on shape was observed for Δhs1431, followed by an intermediate
quantitative effect for Δhs746 (fig. 7B), whereas possible changes in Δhs586 were mildest
and sub-significant after correction for multiple hypothesis testing. These results mirror the
magnitude of expression phenotypes, which were most pronounced in Δhs1431, followed by
intermediate changes in Δhs746 and only a limited expression phenotype observed in
Δhs586 (fig. 6 and fig. S4). In summary, these results demonstrate a significant effect of
enhancer deletions on craniofacial morphology.
Each enhancer deletion causes a distinct set of differences compared to wild-type
morphology. This is evident from the CVA, where the first three canonical variates (CV1-
CV3) most clearly separate wild-type mice from Δhs1431, Δhs746, and Δhs586 respectively
(fig. 7). Each enhancer deletion produces phenotypic effects that are not confined to a single
feature, but involve multiple regions of the skull (fig. 7C, movies S12–S20). For example,
deletion of hs1431 results in an increase in facial length, a relative increase in the width of
the anterior neurocranium and a shortening of the anterior cranial base. In contrast, Δhs746
results in a shortening of the face, a widening of the posterior neurocranium, a narrowing of
the palate and shortening of the cranial base. While both Δhs1431 and Δhs746 have
significant effects on facial morphology in structures derived from regions with enhancer
activity at e11.5 and e13.5 (fig. 6), there are also changes in other parts of the skull. These
correlated patterns of change are consistent with numerous studies demonstrating that
cranium development is a highly integrated process, and that variation of the skull is
structured by complex interactions between the growing chondrocranium, neurocranium and
other nearby tissues (59, 60). Regardless of the precise molecular pathways and
developmental mechanisms that underlie the morphological changes observed upon deletion
of these enhancers, these results demonstrate a direct role of distant-acting enhancers in the
development of craniofacial shape in mammals. The observation of significant, but non-
pathological alterations of craniofacial morphology as a result of enhancer deletions
supports the notion that enhancers contribute to normal variation in facial shape.
Conclusions
The general shape of the human face and skull, the differences in facial shape between
individuals, and the high heritability of facial shape are subjects of broad interest, since they
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have far-reaching implications well beyond basic scientific and biomedical considerations.
Despite rapid progress in the development of tools for correlating genetic and genomic
information with phenotypic traits in human populations, the genetic drivers of variation in
craniofacial features remain poorly explored. In this study, we examined the possible impact
of distant-acting regulatory sequences on craniofacial morphology. Throughout the genome,
we identified several thousand sequences that are likely to be distant-acting enhancers active
in vivo during mammalian craniofacial development. While this epigenomic analysis was
performed in the mouse, the vast majority of these enhancer candidate sequences are
conserved between mouse and human. Large-scale characterization of more than 200
candidate sequences in transgenic mice showed the versatility of enhancers in orchestrating
gene expression during craniofacial development. These observations are consistent with
genome-wide analyses of enhancers active in human neural crest cells, as well as studies of
regulatory sequences associated with individual members of the neural crest gene regulatory
network (23–27). We also demonstrated that deletion of craniofacial enhancers results in
non-pathological, but significant changes in craniofacial morphology in mice. Taken
together, these data support that enhancers play a substantial role in determining craniofacial
shape. Systematic genome-wide studies of normal morphological variation in human
populations are beginning to emerge (15–17) and will offer the opportunity to intersect in
vivo-derived genome-wide maps of craniofacial enhancers identified in this study with
variation data, to gain further mechanistic insight into the molecular underpinnings of
human facial shape and variation therein.
Beyond the spectrum of normal morphological variation in craniofacial shape, these results
also provide a functional genomic framework for the analysis of craniofacial birth defects.
We showed that deletion of craniofacial enhancers results in significant, but non-
pathological changes in morphology. Even for Δhs1431, the enhancer deletion resulting in
the most severe reduction in craniofacial gene expression, the morphological phenotype was
overall much less severe than the pathological changes observed upon deletion of the Snai2
gene itself (61). This milder phenotype is not surprising, considering that remaining baseline
activity of the gene was observed in all craniofacial structures examined (fig. 6A and fig.
S4C). These observations highlight the potential of enhancers to modulate craniofacial
morphology in quantitatively subtle ways, without the pathological consequences potentially
associated with deleterious protein-coding mutations. These results raise the possibility that
sequence or copy number variation affecting more than one enhancer of the same gene may
cumulatively result in more severe and potentially pathological phenotypes. Isolated
examples of sequence variants in distant-acting enhancers associated with malformations
such as clefts of the lip or palate have been described (e.g., (56)) and there is circumstantial
evidence that non-coding sequences, including enhancers, play a significant role in these
processes (e.g., (35)). There is partial overlap between loci involved in normal facial shape
variation and in craniofacial birth defects, supporting the possibility that some
dysmorphologies represent the extreme ends of the normal spectrum of variation (15, 16).
The improved genome-wide functional annotation of craniofacial in vivo enhancers obtained
through this study is expected to aid not only in the functional exploration of isolated studies
of craniofacial dysmorphologies, but may also facilitate an understanding of the links
between normal and pathological variation in craniofacial shape.
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Fig. 1. Study Overview
P300 ChIP-seq was performed on whole mouse face tissue from e11.5 embryos, which
identified 4,399 putative distant-acting craniofacial enhancers. More than 200 craniofacial
candidate enhancers were characterized in depth through LacZ transgenesis in mouse
embryos (LacZ panel), and selected enhancers were further analyzed by optical projection
tomography (OPT panel; unstained tissue is shown in green, LacZ stained tissue is shown in
red). Furthermore, a panel of three enhancers near functionally unrelated genes was studied
by knockout analysis and detailed skull morphometry in mice.
Attanasio et al. Page 12
Science. Author manuscript; available in PMC 2014 April 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 2. Genome-wide identification of candidate craniofacial enhancers
Mouse genome graph showing all p300-enriched regions (green dots) and all 281 sequences
tested in vivo or re-examined for craniofacial activity in this study (red dots). Examples of
selected major craniofacial genes (34) and genomic regions (e.g., 8q24 (35), ABCA4 (36))
are highlighted by pink boxes. Known craniofacial loci were generally enriched in candidate
sequences and were specifically targeted for sampling in transgenic assays (red dots). The
three genomic regions studied by knockout analysis are highlighted by blue boxes.
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Fig. 3. Transgenic characterization of craniofacial candidate enhancers results in the
identification of facial substructure-specific enhancers
(A) Selection of 18 reproducible craniofacial enhancers at e11.5 illustrates the broad
spectrum of activity patterns observed in vivo. For each tested candidate enhancer, one
representative embryo face is shown, the reproducibility of each pattern among multiple
transgenic founder embryos is indicated at the right bottom corner of each image. For each
element, the nearest relevant craniofacial gene, if any, is also provided. Additional embryo
images obtained with each enhancer construct can be viewed at http://enhancer.lbl.gov or
http://facebase.org. (B) Upper panel: Four examples of highly restricted specificity to
craniofacial substructures (see main text). Lower panel: Four examples of internal enhancer
activity captured by OPT scanning of LacZ stained embryos. Green: no LacZ activity
(enhancer inactive), red: LacZ activity (enhancer active). A, anterior; D, dorsal; fb,
forebrain; lnp, lateral nasal prominence; mble, mandibular process; mnp, medial nasal
prominence; mx, maxillary process; P, posterior; V, ventral.
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Fig. 4. Regulatory landscapes of craniofacial loci
(A) Craniofacial enhancers near Msx1, a major craniofacial gene, were identified by p300
ChIP-seq (green boxes). This included the re-identification of a region proximal to Msx1
with previously described enhancer activity (mm426, (50)), as well as four additional, more
distal enhancers with complementary activity patterns. For each enhancer, only one
representative embryo is shown, numbers indicate reproducibility. Red arrows indicate
selected correlations between Msx1 RNA expression (ISH) and individual enhancers (see
main text). Red box indicates enhancer hs746 which was further studied by knockout
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analysis. Msx1 ISH: Embrys database (http://embrys.jp) (51). (B) Identification of
craniofacial enhancers in the cleft- and morphology-associated gene desert at human
chromosome 8q24 (orthologous mouse region shown, (35)). Brown box indicates the region
corresponding to a 640kb human region associated with orofacial clefts (non-syndromic
cleft lip with or without cleft palate, NSCL/P) and devoid of protein-coding genes. Two of
four candidate enhancers within the region drove craniofacial expression. For each enhancer,
lateral and frontal views of one representative embryo are shown. (C) Identification of a
craniofacial midline enhancer at the cleft-associated susceptibility interval at the ABCA4
locus (36). The enhancer is highly active in the nasal prominences (yellow arrows), but not
the maxillary or mandible (pink arrows).
Attanasio et al. Page 16
Science. Author manuscript; available in PMC 2014 April 25.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Fig. 5. Developmental activity patterns of three enhancers selected for deletion studies
The in vivo activity of each enhancer was monitored at different stages of development
(e11.5, e13.5 and e15.5). All enhancers were reproducibly active in the craniofacial complex
during embryonic development, with spatial changes in activity across stages. Side views,
LacZ-stained whole-mount embryos. Front views, optical projection tomography
reconstructed 3D images. Regions of enhancer activity are shown in red. Also see movies
S1–S9.
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Fig. 6. Expression phenotypes resulting from craniofacial enhancer deletions
(A, B) In vivo activity pattern of hs1431 (at e11.5) and hs746 (at e13.5). OPT data is
represented in red (LacZ, enhancer active) and green (no LacZ, enhancer inactive). (C, D)
Expression levels of enhancer target genes in craniofacial tissues dissected from wild-type
(gray) and knockout (red) littermate embryos. Error bars show the variation among
individuals of the same genotype (SEM). *, P < 0.05 (Student T-test, 1-tailed); Mble,
mandibular; Mx, maxillary; MNP, medial nasal process; LNP, lateral nasal process.
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Fig. 7. Enhancer deletions cause changes of craniofacial morphology
(A) Canonical variate analysis (CVA) of micro-CT data from mice with three different
enhancer deletions, compared to wild-type. The 3D morphs show the morphological
variation that corresponds to the first three canonical variates. Renderings show CV
endpoints 3× expanded to improve visualization. (B) Magnitude of shape differences
between wild-type and enhancer null mice, based on Procrustes distances (30). Error bars
indicate standard deviation of shape differences from resampling Procrustes distances across
10,000 iterations. (C) Wireframe visualization of the first three canonical variates, which are
predominantly driven by morphological differences between wild-type mice and Δhs1431,
Δhs746 and Δhs586, respectively. CV endpoints are superimposed as red and blue
wireframes, respectively.
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Table 1
Top enriched annotations of mouse and human phenotypes associated with candidate
craniofacial enhancers
Top: Ten of the twelve most significantly enriched terms from the Mouse Phenotype ontology directly relate
to craniofacial development. The remaining two phenotypes (abnormal axial skeleton morphology and
abnormal skeleton development, not shown) relate to general skeleton development, a process that shares key
signaling pathways with cranial skeleton development (37). Bottom: Six of the ten most significantly enriched
terms from the Human Phenotype ontology are relevant to craniofacial development. The four remaining
phenotypes (not shown) are all associated with limb abnormalities, consistent with previous knowledge of
shared developmental pathways during limb and face development (38–40). In each analysis, only terms
exceeding 2-fold binomial enrichment were considered and ranked by P-value (binomial raw P-values).
Rank Phenotype Term Binomial
P-value
Binomial Fold
Enrichment
Mouse phenotypes
1 abnormal craniofacial morphology 5.8e-110 2.0
3 abnormal head morphology 1.7e-88 2.1
4 abnormal craniofacial development 3.8e-82 2.4
5 abnormal craniofacial bone morphology 1.3e-78 2.1
6 abnormal facial morphology 5.5e-78 2.2
7 abnormal cranium morphology 3.1e-77 2.2
9 abnormal mouth morphology 3.5e-72 2.3
10 abnormal orofacial morphology 1.5e-71 2.3
11 abnormal viscerocranium morphology 1.0e-62 2.3
12 abnormal neurocranium morphology 2.1e-60 2.5
Human phenotypes
2 malar hypoplasia 3.6e-17 2.4
3 abnormality of the midface 7.6e-17 2.3
5 abnormal location of ears 5.7e-16 2.1
7 low-set ears 1.1e-15 2.1
8 abnormality of the fontanelles and cranial sutures 1.2e-15 2.2
9 abnormality of the calvarium 1.3e-15 2.1
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